David Oxlade joins TranScrip Partners
This article was originally published in Scrip
Executive Summary
TranScrip Partners, a pharmaceutical development company formed in 2008 to provide advice and support to pharmaceutical and biotechnology companies, has appointed David Oxlade chairman of the board. In 2006, Mr Oxlade was appointed chairman of BioAnaLab, which was acquired by Millipore this year. He is the former CEO of Xenova, and, prior to their acquisition by Roche, he also spent 14 years working for Boehringer Mannheim and seven years serving as president of Syva.